Cigna's Beat-and-Raise Comes With a 2027 Air Pocket
A strong third quarter and a higher 2026 EPS floor collide with a softer pharmacy-benefit outlook, a slower biosimilar pipeline, and the ACA exit.
CI · Earnings Call · 2026-11-05
The beat is clean; the bridge is not
Cigna's third quarter was the kind of print a mature healthcare compounder wants: adjusted revenue of $73.8 billion, adjusted EPS of $7.98, and a raised 2026 floor of at least $30.60. “Our strong performance through the first 9 months of the year gives us confidence to raise our full year outlook.” — Brian C. Evanko, President and Chief Executive Officer · 2026-11-05 The tape is not screaming distress: CI is up 8.8% over 90 days and only 4.6% below its October 22 peak, even though it remains 17.8% below the 2024 high. The real event on the call was not Q3. It was management's first real scaffolding for 2027—and the market now has to underwrite a deliberate earnings air pocket in pharmacy benefit services.
The 2027 air pocket sits in PBS
Brian Evanko framed 2027 as at least 10% EPS growth off a roughly $30 run-rate, but the mix is uneven: Cigna Healthcare grows 6%–9%, Specialty & Care grows at the low end of its 8%–12% long term growth algorithm, and Evernorth rises only low single digits. The pinch is Signature model-era pharmacy benefit services, where management now expects income to fall by single digits.
Which implies our pharmacy benefit services income will be down single digits in 2027 from where we are in 2026... due to the industry wide pressure on gross rebate pools. As well as a downtick in the percentage of employers covering GLP-1s for weight management.
That is a more explicit negative than the 'transitional years' language investors heard in prior quarters. The ACA exchange business exit adds about $200 million of headwind and a $0.60 drag to the 2027 run-rate, though Ann Dennison said the company would look to recapture stranded overhead in 2028.
This is not a demand collapse. It is a reset of the PBM profit pool: rebate compression is industry-wide, and employer coverage of GLP-1s for weight loss is ticking down. The company also keeps pointing to a strong 2027 selling season—retention in the high 90s and at least 2 million new PBS customers—which is why the stock has not broken. But the quality of the 2027 story is lower: more of the growth has to come from Cigna Healthcare, stop loss, and cost cuts, not from the PBM.
The specialty tailwind becomes a 2027 headwind
The sharpest contrast with prior calls is in specialty. In July, Ann Dennison was still saying, “We expect Specialty generics and biosimilars to be a meaningful tailwind.” — Ann Dennison, Chief Financial Officer · 2026-07-30 On this call, Brian said “for 2027 specifically, again, the pipeline indicates less material new biosimilars and specialty generics being introduced. But I would view that as a temporary slowdown.” — Brian C. Evanko, President and Chief Executive Officer · 2026-11-05 Same business, different slope. Cigna still expects Specialty & Care to grow within its long-term range, but at the low end, because the next wave of oncology and MS biosimilars under the medical benefit arrives later in the decade. That matters because medical benefit exposure is one of the company's under-penetrated growth lanes—only 6%–7% share, by Brian's estimate—so 2027 is a waiting year, not a harvest year.
The 340B program question returned, but management kept it in perspective: Accredo's contract-pharmacy exposure is a small contributor to Evernorth earnings, and the 2027 pressure is modest rather than a call-out headwind. That is a useful tell. The bigger issue is not a new regulatory shock; it is the natural cadence of generic and biosimilar launches.
Signature moves from evangelism to build phase
Cigna has spent several quarters selling the Signature model as a rebate-free, fee-based redesign. This quarter the language shifted from vision to implementation: design complete, build phase underway, manufacturer and pharmacy contracts being renegotiated, and the Cigna Healthcare fully insured book adopting on January 1, 2027. The broader EverNorth book is still a 2028 story. In the first quarter, Brian had said the company expected “at least 50% of our Evernorth Pharmacy Benefit Services members to be in the Signature model by year-end 2028.” — Brian Evanko, President and Chief Operating Officer (incoming CEO) · 2026-04-30 That target is intact, but the revenue and margin benefit is back-end loaded.
The strategic logic is sound: align with the Consolidated Appropriations Act and the Department of Labor's PBM fee-disclosure rule, reduce fiduciary risk for employers, and guarantee patients the lowest out-of-pocket cost. The near-term cost is also clear: transition spend, recontracting, and a lower 2027 PBS base. The company is asking investors to look through that trough to 2028 adoption.
What offsets it: cost cuts and a low bar
The offset is distinct capabilities plus a cost program. Accelerate to 1 targets $3 billion of gross run-rate savings by 2030; Ann said 70%–80% comes from automation, modernization, and talent effectiveness, with 20%–30% from vendors. “We are gonna fund reinvestment in the business, so not all of it is going to fall to the bottom line.” — Ann Dennison, Chief Financial Officer · 2026-11-05 That is the right caveat. The program supports the 10%–14% long-term EPS algorithm, but it is not a 2027 EPS rescue by itself.
The fundamental base is large but thin-margin. The last filed quarter showed $71.7 billion of revenue, up 7% year over year, while net margin was just 2.6%. At 10.4x trailing earnings, the market is not pricing Cigna as a high-growth compounder. That cuts both ways: expectations are modest, but the company still has to prove that the 2027 PBS decline is a bridge and not a new baseline.
The bottom line
Cigna's quarter was strong enough to raise 2026, but the call was really about 2027. The company now has a clearer—and less flattering—bridge: ACA exit costs, a down PBS year, a slower biosimilar pipeline, and a Signature model that does not scale in earnest until 2028. Against that, it has a still-growing employer health business, a stop-loss loss book recovering toward target margins, and a credible cost program. The stock's proximity to its recent high says investors are willing to wait. The burden of proof now shifts to the 2028 selling season and to whether personalization at scale can actually bend the cost curve enough to make the PBM reset look temporary.